Study shows that Kerry’s BC30™ supports digestive health in healthy Chinese adults

A recent clinical study showed that BC30™ (Heyndrickxia coagulans GBI-30, 6086), a spore-forming probiotic developed by Kerry Group, significantly improve gastrointestinal and digestive functions in healthy Chinese adults with irregular bowel movements.

The randomised, double-blind, placebo-controlled trial was conducted at the Beijing Institute of Geriatrics, Beijing Hospital, National Health Commission, China. Over a 28-day period, 111 healthy adults aged 18–65 consumed 1 billion CFU/day of BC30™ in a ready-to-mix nutritional sachet rehydrated in a beverage. Prior to the study, participants reported irregular bowel movements, defined as 4 or fewer bowel movements per week or 2 or more loose stools per week.

The following are the key findings of the study:

• Improved Digestive Function: Participants consuming BC30™ experienced a statistically significant increase in stool frequency and improved fecal consistency.
• Symptom Relief: Significant improvements were observed in overall GSRS (Gastrointestinal Symptom Rating Scale) scores, particularly in abdominal pain and constipation, during the final 2 weeks of the study.
• Microbiome Modulation: BC30™ intake led to increased levels of Bacteroides spp. and decreased levels of Clostridium spp., indicating positive modulation of the gut microbiota.
• Well-Tolerated: No adverse effects were reported, confirming BC30™’s safety and tolerability.

This study marks the first clinical validation of BC30™ in an Asian population, expanding the global relevance of its digestive health benefits. The trial was registered at ClinicalTrials.gov (NCT06644001) and published in Beneficial Microbes¹.

Dr. Mathieu Millette, RDA Director, Digestive Health, Kerry mentioned that the study reaffirmed the versatility and afficacy of BC30™ across diverse populations.

With over 65 published studies, BC30™ is recognised for its stability, safety, and efficacy in digestive health and protein utilisation. It is U.S. FDA-notified GRAS and accepted by regulatory bodies globally.

BC30™ is part of Kerry’s portfolio of science-backed solutions tailored to meet digestive health needs of consumers around the world.